ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 506

Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis

Osamu Saiki1, Hiroshi Uda1 and Koji Shigematsu2, 1Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, 2Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: For active rheumatoid arthritis (RA) patients with inadequate response to synthetic DMARDs, biologic agents, such as TNF inhibitor and IL-6 receptor inhibitor, are indicated. However, all biologics are very expensive, and, therefore all patients with high disease activities always can not receive biologics. Indeed, the interval of administration is fixed in most of biologics, but the interval is flexible in some biologics such as etanercept and infliximab. Tocilizumab (TCZ) is one of useful biologics, and the interval of TCZ infusion is fixed for 4 weeks. In the course of treating active RA patients by TCZ with 4 weeks interval, sometimes we experienced that longer interval was also effective. In preliminary study, we found that six weeks interval was effective in these patients. The present study is carried out to clarify the efficacy of six weeks interval of TCZ infusion in the patients with active RA.

Methods: The patients who showed inadequate response to DMARDs and the patients who showed inadequate response to biologics other than TCZ and who agreed with TCZ therapy of six weeks interval were enrolled in the present study. In addition to oral medicines, the patients were infused 8mg/kg of tocilizumab in every six weeks (SIWETO study). The clinical assessments and blood tests were also carried out in every 6 weeks. To the patients who did not achieve clinical remission by 6 weeks interval of TCZ, prednisolone (PSL) and/or methotrexate were added with increasing the dose. The patients who achieved clinical remission in 12 months were estimated as responder and others were as non-responders. We followed up the patients at least for 3 years. 

Results: Total of 74 patients was enrolled in the present study. Male and female were 18 and 56 respectively. Forty-four patients achieved clinical remission with 6w interval, and the rest of the patients were non-responder. To the patients who did not achieve clinical remission with 6w interval, TCZ infusion with 5w or 4w interval was carried out. Nineteen patients achieved clinical remission by 5w interval and four patients by 4w interval, respectively. The rest of 7 patients could not achieve clinical remission by TCZ infusion. In 44 patients who achieved clinical remission with 6w interval of TCZ infusion, 10 patients were treated by TCZ alone without any oral medicines for rheumatoid arthritis and kept the condition throughout the observation and the rest of patients received either or both PSL (1 to 7.5 mg) and MTX (2 to 8mg). It is generally accepted in Japanese rheumatologist that the effective dose of MTX in Japanese is lower than that in Caucasian. Severe adverse events including tuberculosis and death were not found. The frequency of other adverse events of 6w interval of TCZ was less than those of regular use (4w interval).  

Conclusion: The SIWETO study provides evidence that 6w interval of TCZ infusion is also effective in active rheumatoid arthritis patients. The finding of SIWETO study is quite useful for taking care of active rheumatoid arthritis patients, especially in financial aspects. The cost of 6 weeks interval of TCZ became two thirds of that of 4 weeks regular use.


Disclosure:

O. Saiki,
None;

H. Uda,
None;

K. Shigematsu,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trial-of-six-weeks-interval-of-tocilizumab-infusion-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.